GIANT BioSystems, founded by a team of elite scientists from leading institutions such as Cornell, Caltech, Harvard, UCLA, and MIT (Dr. Ehsan Shirzaei Sani, CEO/Co-Founder; Dr. Morteza Azizi, CTO/Co-Founder; Canran Wang, COO/Co-Founder; and Samuel Solomon, CSO/Director of AI), is pioneering an AI/ML-assisted microfluidics-based platform for high-throughput antimicrobial susceptibility testing (AST) and drug/antibiotic discovery. GIANT’s patented microfluidics chip facilitates the simultaneous screening of over 50 antibiotics in just 3-5 hours with exceptional precision. The GIANT platform is cost-effective, compact, highly precise, and user-friendly, requiring no complex training.
Sacyl Pharmaceuticals (SACYL) aims to develop potent soluble adenylyl cyclase (sAC) inhibitors into first-in-class systemic, non-hormonal, on-demand contraceptives for men and women with the goal to significantly contribute to increased use of modern contraceptives among couples to reduce unintended pregnancies, improving families’ health and well-being globally.
Carbon mineralization is a natural process. Carbon to Stone perfected a reactive crystallization process that matches the scale and speed of climate crisis demands.
EIR Biopharma, Inc. is an early-stage privately held biotech company developing therapeutics for the treatment of eye disease.
INLAN is leveraging the most recent advancements in RFID technology to provide item-level monitoring and tracking solutions for manufacturing, supply chain, and retail. INLAN is committed to bringing RFID tags as an affordable, scalable, and extremely precise solution for indoor tracking and automatic navigation systems.
DASH Materials, Inc. develops point-of-care DNA/RNA detection kits for infectious diseases, from healthcare to agriculture. The platform aims to realize the sensitivity and specificity of nucleic acid testing like PCR with the ease, speed, and portability of qualitative antigen tests.
UbiquiTx, a spin-out from Cornell University and MIT, is focused on leveraging machine learning and protein engineering to develop programmable protein-modulating therapies. The company’s computational platform allows the designing of motif, mutant and PTM-specific peptides to pathogenic proteins from sequence alone based on known interactions found in nature.
Check back for additional information once the company emerges from stealth mode.
EzraBio is a company providing researchers with the ability to perform ribosome profiling from a wide range of biological samples with ease. By looking into global translation with superior resolution, it is now possible to uncover hidden coding potential, dissect translational response, identify tumor-associated antigens, and guide mRNA therapeutics.
Mission-Driven Tech is a women’s health venture dedicated to the transformation of gynecologic cancer care with modern technology.